Table 1. Intracranial activity of select tyrosine kinase inhibitors approved or in development for treatment of NSCLC, breast cancer, or melanoma.

Abbreviations: ALK, anaplastic lymphoma kinase; BICR, blinded independent central review; CDCR, CNS disease control rate; CI, confidence interval; CNS, central nervous system; EGFR, epidermal growth factor receptor; HER2, human epidermal growth receptor 2; HR, hazard ratio; ICRR, intracranial response rate; IDCR, intracranial disease control rate; ITT, intention‐to‐treat; NSCLC, non‐small cell lung cancer; ORR; objective response rate; PFS, progression‐free survival; ROS1, c‐ros oncogene 1; TKI, tyrosine kinase inhibitor.